LY3415244
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor
Trial Timeline
Nov 22, 2018 → Oct 9, 2019
NCT ID
NCT03752177About LY3415244
LY3415244 is a phase 1 stage product being developed by Eli Lilly for Solid Tumor. The current trial status is terminated. This product is registered under clinical trial identifier NCT03752177. Target conditions include Solid Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03752177 | Phase 1 | Terminated |
Competing Products
20 competing products in Solid Tumor